BPH Corporate Limited ACN 95 912 002 PO Box 317, North Perth, Western Australia 6906

14 View Street, North Perth, Western Australia 6006 admin@bphcorporate.com.au www.bphcorporate.com.au

T: +61 8 9328 8366 F: +61 8 9328 8733

t:\- bph corporate ltd\announcements\2010\bph presentation.doc

19 March 2010 Companies Announcements Office Australian Securities Exchange Limited 10th Floor, 20 Bond Street SYDNEY NSW 2000 Dear Sir/Madam

BPH Corporate Presentation BPH Corporate Ltd is presenting to brokers and investors in Europe this week. A copy of the presentation is attached. Yours sincerely,

David Breeze Chairman

19/03/2010

1

BPH Corporate Limited[ASX: BPH]

March 2010

BPH Corporate Limited [ASX: BPH] is an Australian Securities Exchange listed company with investments in resources and developing biomedical research and technologies within Australian Universities and Hospital Institutes.

BPH Corporate has recently exercised an exclusive option to invest into an unlisted Oil

Executive Summary

p y p& Gas Exploration and Production company – Advent Energy Ltd. The option allows for BPH to increase its interest from 9.7% to 19.5% of Advent’s share capital at 50c per share, consistent with the Talbot Group Holding’s investment (Nov 2008).

BPH provides early stage funding, project management and commercialisation strategies for proof of concept for a direct collaboration, a spin out company or to secure a license, whilst the institutional partner provides infrastructure and the core

i tifi tiscientific expertise.

Three of BPH’s projects have advanced to a stage where we have been able to initiate discussions on commercialisation with domestic and international companies. The most recent development in the novel anti‐mitotic cancer therapeutic area addresses a market valued at in excess of one billion dollars (US) per year.

19/03/2010

2

Corporate Structure & Placement Summary

BPH Corporate Limited ASX: BPH•Shareholders: 2,771Shareholders: 2,771•Shares on Issue 206,938,246•Market Capitalisation $14.9 million

(10 March @ $0.072)

Director & Company Secretary

Deborah Ambrosini

Chairman

David Breeze

Non-Executive Director

Goh Hock

Non-Executive Director

Greg Gilbert

Scientific Advisor

Professor Peter Klinken

Scientific Advisor

Dr Robin Scaife

Project/Investment Structure(Post Spin‐off, Placement, Investment)

BPH Corporate Ltd

Molecular Discovery Systems (MDSystems)

Anti‐Mitotic Cancer Therapeutics

Drug Screening

Diagnostic Array Systems (DAS)

Infectious Disease Molecular Diagnostic Tests

Cortical Dynamics

Advent Energy Ltd

Asset Energy Pty Ltd

19.21% Increasing to 19.5%

100%

UWA / BPH Corporate JV

HLS5 and Associated Technologies

Cortical DynamicsAnaesthesia / Brain ActivityMonitor

Synthetic Enhanced Raman Spectroscopy (SERS)

100%

19/03/2010

3

Novel Anti‐Microtubule Cancer Therapeutics

Our Technology

Unregulated cell growth and evasion of cell death are two of the fundamental hallmarks of cancer.

BPH has recently identified new anti‐cancer agents that inhibit cancer cell l f b l f ll hproliferation by selective induction of cell death.

Microtubule drugs are considered to be among the most clinically useful cancer therapeutics discovered to date, and generate revenue well in excess of one billion USD per year. In light of the clinical success of microtubule drugs such as the blockbuster therapeutics Taxol® and Vinorelbine ®, the identification of new and improved microtubule drugs remains an important objective of current oncology drug discovery.

Stage

Currently in the proof‐of‐concept stage, the project is utilising the MDSystems high content platform and in vivo trials.

In addition to lead optimisation through in silico and in vitro medicinal chemistry, BPH is also actively engaged in pharmaceutical development of clinically suitable forms of the new anti‐cancer drugs.

Novel Anti‐Microtubule Cancer Therapeutics

Data

The exceptional clinical relevance of anti‐microtubule drugs is due to their ability to directly kill dividing cells (Figure 1), as well as their effect on the tumor vasculature (Figure 2)their effect on the tumor vasculature (Figure 2).

Our data supports these mechanisms of action.

Intellectual Property

The compounds isolated using our drug screening technology are novel and

Figure 1 Figure 2

protected via provisional patent application.

Potential

BPH aims to progress the research program through preclinical drug development, at which point a co‐development partner will be sought to undertake clinical trials.

19/03/2010

4

Advent Energy Exclusive Investment Option:

‐ Increase interest to 19.5% of Advent

A$0 50/shareA$0.50/share

A$14 million total investment

Investment Highlights

•Cornerstone project – offshore Sydney Basin / Petroleum Exploration Permit (PEP) 11• Permit potential of 16.3 Tcf recoverable plus liquids• 8,250 km2 undrilled highly prospective area adjacent (<50km) to Australia’s largest market and

massive infrastructure• Earning 85%

•Proven management team• Former leadership positions in

major O&G companies and oilfields

• Wealth of finance and corporate structuring experience

•Portfolio of onshore and offshore permits with near‐term production potential

• Near term production projects inNear term production projects in producing basins

• Multitude of highly prospective play types and leads for future exploration upside

•Drilling anticipated 3rd Q 2010• Taking advantage of significant

reduction in rig rates / unused rig slots

19/03/2010

5

Advent Energy Ltd

Background Key Personnel

•Formed in 2004 as an unlisted oil and gas exploration and production company based in Perth, Western Australia

•Has a portfolio of assets both onshore and offshore Australia that have had an estimated USD 126m spent on historic exploration

•Portfolio estimated P10 prospective recoverable resources of approximately 13.9 Tcf gas and 139 MMbbl oil/condensate Net to Advent, excluding additional corporate interests and newly determined hydrocarbon plays

Mr Goh Hock – Chairman: A former President of Schlumberger Asia and then a Global Divisional President of Schlumberger during a 25 year career in the oil and gas industry spanning over 10 countries through Asia (incl. Australia), the Middle East and Europe.

Mr David Breeze – Executive Director: A professional company director with extensive experience in transaction structuring, corporate advisory and funding for listed and unlisted companies.

p y y p y

•Secured funding agreements from Talbot Group Holdings for AUD 7 million and BPH Corporate for AUD 14 million as part of equity issue of 55 million shares at AUD0.50 per share

•Company currently held mainly by MEC Resources (ASX: MMR), BPH Corporate (ASX: BPH) and Grandbridge Ltd (ASX: GBA).

Mr Ding Gui Ming – Geology Advisory Panel Chair: A former Chinese Government Vice Minister. Previously held the positions of President of Daqing Oil and Head of Exploration for the China National Petroleum Company (CNPC), where he directed the exploration activity of more than 20 oilfields in China.

Mr Eng Hin Tan – Non‐executive Director: A private equity investor who previously worked with Schlumberger Oilfield Services in India, Brunei, Indonesia and Malaysia.

Ms Deborah Ambrosini – CFO & Co Secretary: A corporate accountant with over 10 years experience in accounting and corporate development spanning the biotechnology, mining, IT communications and financial services sectors.

Mr Jim Dirstein ‐ petroleum geophysicist with over 25 years experience, specialising in cutting‐edge technologies to improve corporate

Shareholder Structure (assumes BPH investment at max level)

p g g g g p pexploration/exploitation work flows.

Mr Tim Berge – Internationally recognised and published geophysicist with over 30 years of experience.

Mr Lan Nguyen – Ex MD of Mosaic Oil (ASX: MOS). Over 20 years experience in O&G industry across geophysics, geology, reservoir and production engineering and drilling and completion engineering.

Mr Fred Kroh – Seismic processing specialist and former Project Leader of the Geophysical Processing and Data Access Project for Geoscience Australia.

Mr Phil Duff – Drilling Services manager and former General Manager of AGR‐Peak

• NSW/PEP 11 covers 8250 sq km, 20 km from Australia’s largest energy market, excellent infrastructure

• Permit Prospective Recoverable Resources estimated at up to 16.3 Tcf; mean = 7.5 Tcf

• Excellent analogies with world class producing fields

Offshore Sydney Basin : PEP11 Opportunity

• Excellent analogies with world class producing fields

• Active thermogenic hydrocarbon system demonstrated offshore

• Possible gas/condensate-charged Permian + Triassic reservoirs / excellent potential for gas & oil discovery

• Prospective resources and proximity to infrastructure infer potential for LNGp

• Advent – right to earn 85%; JV partner Bounty Oil & Gas reducing from 75% to 15%

• Robust Economics

• Advanced negotiations for rig, environmental approvals and drilling engineering design nearing completion

19/03/2010

6

Portfolio Volumetric Estimate of Prospective Net Recoverable Resources

Block Asset Type Advent’s Interest Prospective Recoverable Resources Net to Advent (Bcf)

Recoverable Resources Oil / Cond. / LPG Net to Advent (MMbbl)

P90 P50 P10 P90 P50 P10

PEP11 Fish Gas Prospect 85% 416.8 2,010.9 7,807.4 4.2 20.1 78.1

Baleen Gas Prospect 85% 188 2 1 524 9 4 911 8 1 9 15 2 49 1Baleen Gas Prospect 85% 188.2 1,524.9 4,911.8 1.9 15.2 49.1

Sei Gas Lead 85% 94.1 164.7 238.6 0.9 1.6 2.4

Humpback Gas Lead 85% 121.0 205.0 299.1 1.2 2.1 3.0

Orca Gas Lead 85% 144.5 265.5 383.2 1.4 2.7 3.8

Blue Gas Lead 85% 87.4 144.5 215.1 0.9 1.4 2.2

1,052.0 4,315.6 13,855.2 10.5 43.2 138.6

EP325 Rivoli Proven Gas 8.3% 0.5 0.8 1.27 0.0 0.0 0.1

Rivoli Deep Gas Prospect 8.3% 1.8

0.5 0.8 3.1 0.0 0.0 0.1

EP 386 / RL‐1 Weaber Gas Project 100% 52.8

TOTAL 1,053 4,316 13,910 10.5 43.2 138.7

•Advent has right to increase its interest to 85% from 25% in PEP11 by drilling one well.

•PEP11 covers over 8,250km2 and lies directly adjacent to the heavily populated and industrialised central coast of NSW. Major prospects are located less than 50km from Sydney and Newcastle.

•No drilling has taken place in the offshore Sydney Basin. Since 1910, 66% of onshore petroleum exploration wells have shown hydrocarbons and 41% have flowed gas on test

Portfolio – Offshore Sydney Basin PEP11

gas on test.

•For 175 years coal has been mined from the Newcastle coalfields in the Hunter Valley.

•Comparisons with Moonie Oil Field

•Active hydrocarbon seepage has been detected along the PEP11/continental margin

•LandSat imagery interpretation demonstrates repeated slicks over the Baleen prospect.

•Inshore hydrocarbon seepage has been analysed to reveal a thermogenic source, with detected liquid component.

•Significant hydrocarbon and migration features have been observed in 1981,1991 and 2004 seismic profiles.

•Features include gas chimneys, HRDZs, anomalous AVO, reverse polarity events, and possible flat spots.

19/03/2010

7

Portfolio – Offshore Sydney Basin/PEP11 (cont’d)

•Prospective recoverable resource estimates have been independently validated:•Integration of 1981, 1991, and 2004 seismic data has confirmed Baleen and Fish prospects as constituting very large prospective structures•Combined total prospective resources for the permit’s prospects and leads are estimated at up to 16.3 Tcf (P10) of recoverable gas, 13.8 Tcf Net to Advent

•Plus three new leads identified of prospective multi‐Tcf Original Gas In Place (OGIP)•Advent is currently negotiating to secure a rig slot to drill the Fish Prospect (up to 9.2 Tcf) in PEP11 in 2010. Environmental Approvals have been lodged; drilling engineering design and well testing design has been completed.

Portfolio – Offshore Sydney Basin/PEP11 (cont’d)

Brazilian Oil Field Analogue

19/03/2010

8

Hydrocarbon Migration

North Rankin, Carnarvon Basin

Lord Howe Rise:

Offshore Sydney Basin – Hydrocarbon Migration and HRDZ.

•4.5 billion boe•98.5% methane

North Rankin, Carnarvon

HRDZ

PEP11 Offshore Sydney Basin

[Fred Kroh, Geoscience Australia]

“…sea floor spreading commenced at 65-70 million years before present resulting in the separation of the Lord Howe Rise from the east coast of New South Wales (NSW Bureau of Mineral Resources)”

“a speculative estimate of petroleum resources within Australian jurisdiction on the Lord Howe Rise is about 4.5 billion barrels of oil equivalent (Willcox & Symonds, 1997)”.

“Ocean Drilling Program (ODP) Leg 164 recently drilled three locations on the crest of the Blake Ridge to assess the composition and amount of gas in its gas hydrate deposit (Paull et al, 1996). All gas recovered exceeded 98.5% methane.”

Kingfish, Gippsland

19/03/2010

9

Portfolio – Offshore Sydney Basin/PEP11 (cont’d)

Norway: 5th largest oil2nd largest gas(global exports)Source: EIA and IEA

Norway:OrmenLange

Sydney Basin Continental Margin

Slope Failure Production

14 Tcf

Source: European Commission Slumps: over 28 cu. km

Portfolio – Offshore Sydney Basin/PEP11 (cont’d)

Source: Whelan, Marine & Petr Geol 2005

Gulf Coast transect: general schematic diagram of subsurface oil and gas flow

Nearly all the important oil producing regions of the world were first discovered by surface oil and gas seeps (Hunt, 1981)

diagram of subsurface oil and gas flow consistent with geochemical, geological, and fluid flow modelling (from Whelan, Marine & Petr. Geol. 2005)

19/03/2010

10

Gas Bubbles/Thermogenic Hydrocarbon Seepage

Redox Anomaly

Portfolio – Offshore Sydney Basin/PEP11 (cont’d)

Gas Chimney

MoundAmplitude Anomaly;Brazilian Analogue

AVOGas Chimney

Flat Spot? Pockmark HRDZ

Apparent Gas Reservoired at 1.0 – 2.2 sec TWT

AVO

Total Depth

B4‐15 Full Stack seismic dataCSIRO: “AVO analysis shows indication of class III AVO classification. Class III AVO anomaly generally stands for gas sands.” “Soft” high amplitude

reflectors

AB

Zones of Interest

Zones of interest

Line B4-15

Fugro; John Cant Validation

19/03/2010

11

Total Depth

Interval velocity profile from Fugro

AB

Stacking velocities are 50% lower in highlighted areaZones of Interest

Zones of interest

Return to Contents

B4-15 B4-16

B4-15B4-16B4-17B4-18B4-19B4-20

PEP11: Distribution of Gas Chimneys

B4-17 B4-18

B4-19 B4-20

J. Whelan: “seismic signals are smeared to considerable depth as a result of vigorous gas seepage”

19/03/2010

12

B4-16 Preliminary Final PSTM (Zoom)

Data reprocessing from phase 2, 2009 indicates a flat spot on the time processing withinprocessing within structure on line B4-16 which may warrant further investigation.

Area of interest is cmp900 to 1060 (2 kms) at a time of 1500ms and

www.fugro.com

1700ms.

Note polarity of flat spots is opposite to the seafloor indicating a likely soft response.

B4-16 Preliminary Final PSTM (Zoom)

Data reprocessing from phase 2, 2009 indicates a flat spot on the time processing withinprocessing within structure on line B4-16 which may warrant further investigation.

Area of interest is cmp900 to 1060 (2 kms) at a time of 1500ms and

www.fugro.com

1700ms.

Note polarity of flat spots is opposite to the seafloor indicating a likely soft response.

19/03/2010

13

New South Wales : State of the Market (AGL, NSW Min. Exp. & Inv. Conf.)

Portfolio – Offshore Sydney Basin/PEP11 Market Dynamics

The LNG Industry’s historical inflection point

2005

19/03/2010

14

Portfolio

Carnarvon Basin (Western Australia) EP 325

•Advent holds an 8.3% interest in EP 325, in the Exmouth sub‐Basin of the Carnarvon Basin. The Rivoli Joint Venture Operator is Strike Oil. The Rivoli Gas Field contains a contingent resource of 9.5 Bcf on a Pmean basis.

•Seven wells drilled within EP 325 and adjacent EP 423 f d t Ri li 1 d iblEP 423 found gas at Rivoli‐1, and possibly Bundegi‐1. Enfield Oil Field (40km to the NW of EP 325) produces 5,430 bbl/day and is estimated to contain 150 MMbbl of recoverable oil. The Pyrenees field directly to the north of EP325 contains up to 120 MMbbl of recoverable oil and was expected to produce approximately 96,000 bopd.

•Drilling and production infrastructure in the area is good with a deep water loading jetty and support facilities at Exmouth.

•Rivoli JV in discussions with Australian Department of Defence to supply Exmouth’s Harold E. Holt Naval Communications facility with gas, to replace diesel power generation.

Portfolio

Bonaparte Basin (WA/NT) EP 386 / RL‐1

•The Bonaparte Basin is a proven hydrocarbon bearing sedimentary basin straddling the border between the Northern Territory and Western Australia. It comprises onshore (20,000 km2) and offshore (250,000 km2) components.

•Advent holds 100% of onshore permits EP 386 (WA) andAdvent holds 100% of onshore permits EP 386 (WA) and RL‐1 (NT).

•RL‐1 holds the Weaber Gas Field (Geoscience Australia estimate the Weaber field reserves at 4.3 MMboe) and 2 related prospects – Weaber North and Weaber Southwest.

•3 Discoveries have been made so far in EP 386 – Vienta, Waggon Creek and Bonaparte with estimated recoverable gas resources of 8, 12 and 4 Bcf respectively. Log porosities of 22% and gas flows to 1.3 MMcf/day haveporosities of 22% and gas flows to 1.3 MMcf/day have been recorded.

•Advent has commenced discussions with nearby mineral and diamond resource projects for energy and power supply.

•Recent independent and unpublished review has indicated a significant increase in prospective volumes –“tight gas” plays.

19/03/2010

15

>> Demonstrate the value potential in PEP11 offshore Sydney Basin>Exploration drilling targeting up to 9.2 Tcf 2010

•RPS Group completing environmental approvals •Du El Drilling Services completing well construction + project

Strategy

•Du‐El Drilling Services completing well construction + project management•Advanced stage of negotiation for provision of rig to drill Fish Prospect; TD 2000 m•Seeking equity and/or farmin partners

>Follow up 3D seismic programme (uncommitted)>Follow up appraisal / exploration well(s) (uncommitted)>Evaluate development scenario(s) / attract major partner

>> Production => cashflow from other assets: EP325 / EP386+RL1 anticipated within 18 months

>> Existing corporate activity under consideration

Data, advice, review and technical contributions gratefully acknowledged•Jim Dirstein - -Total Depth - Principal Geophysical Consultant PTEM survey •Fred Kroh –Formerly Project Leader of Geophysical Processing and Data Access Project - Geoscience Australia •Tim Berge –Geophysical Consultant -•Deet Schumacher -Terraliance•Dan Orange •Fred Aminzadeh

Publications

•AAPG Memoirs ”Hydrocarbon migration and its Near surface Migration” •Judd A and Hovland M “Seabed Fluid Flow”•Whelan J Marine Chemistry and Geochemistry, Woods Hole Oceanographic Institution “Dynamic gas driven petroleum systems” and Whelan J et al “Surface & subsurface manifestations of gas movement through a N-S transect of the Gulf of Mexico”•Government of NSW “New South Wales Petroleum Potential”•NSW Department of Mineral Resources•Alder et al “Prospectivity of the Offshore Sydney Basin –A New Perspective“•Frog Tech Pty Ltd

Contributions Gratefully Acknowledged and References

•David Connolly•Michael Abrams•Professor Ron Boyd –Newcastle University •Andrew Mayo –Macquarie Oil –•Kriton Glenn –Geoscience Australia• Ben Clennel , Asrar Talukder and team (CSIRO Subsurface Prediction and Description ) •Geoff O’Brien –Formerly Geoscience Australia•Ding Gui Ming –Principal Geological Consultant•Associate Professor Jock Keene –Sydney University•Kevin Ruming - School of Environmental and Life Sciences University of Newcastle•BOS•Oil Hunters•Bounty Oil

•Aftenbladet Multimedia •The European Commission “The Deep Sea Frontier”•Aminzadeh, F., de Groot, P., Berge, T. et al “Determining Migration Pathway from seismically derived Gas“•Geoscience Australia –Patchett.A and Langford. R.”New South Wales –Deep Saline Aquifer Storage Potential”•Geoscience Australia Glenn. K “Revealing the continental Shelf off New South Wales”•Aminzadeh F Connolly D and Ligtenberg H “Hydrocarbon Phase detection and other applications of Chimney Technology”•Dietmar Schumacher, Surface geochemical exploration for oil and gas: New life for an old technology Geo-Microbial Technologies, Ochelata, Oklahoma, U.S. The Leading Edge•Michael A. Abrams “Significance of hydrocarbon seepage relative to petroleum generation and entrapment” Marine & Petroleum Geology•AAPG Conference Geoffrey W O’Brien, Andrew Barrett, and Megan Lech .”Integrating 3D Seismic data and multiple, independent remote sensing technologies to constrain near-surface Hydrocarbon Migration and Seepage Rates and Leakage Mechanisms on the North-western Australian Margin”

•RPS •BGP •John Cant•Allan Williams -NPA•Mike Rego – Aminex•Tom Fontaine•Fugro•Geosience Australia •Crown Minerals NZ•Kieth Woolard•David Orth •David Remus•Clem Allsworth

North western Australian Margin•Journal of Geophysical Research, The world’s most spectacular marine hydrocarbon seeps (Coal Oil Point, Santa Barbara Channel, California): •Marine & Petroleum Geology N. Rollet, GA Logan, JM Kennard, PE O’Brien, AT Jones, M Sexton Characterisation and correlation of active hydrocarbon seepage using geophysical data sets: An example from the tropical, carbonate Yampi Shelf, Northwest Australia•Daniel Lewis Orange The implications of Hydrocarbon seepage, gas migration and fluid overpressures to frontier exploration and geohazards•Dietmar Schumacher AAPG Hedberg Conference Near Surface Hydrocarbon Migration; Mechanisms and seepage rates The Dynamic Nature of Hydrocarbon Microseepage: An Overview•O’Brien et al “Yampi Shelf Brows Basin –Northwest Shelf “•Cowley R & O’Brien ”Identification and interpretation of leaking hydrocarbons using seismic data“•Kroh F Reprocessing shows AVO potential for petroleum exploration Geoscience Australia

19/03/2010

16

BPH Investments/Projects Cont’d:

Molecular Discovery Systems

Molecular Discovery Systems (MDSystems) is a 19.5% owned subsidiary of BPH Corporate Limited. BPH intends to list MDSystems on the ASX in 2010.

The main business is drug discovery and the validation of biomarkers for disease, therapy and diagnostics.

MDSystems also provides screening services using the core expertise in high content analysis for researchers world‐wide.

The MDSystems owned InCell Analyser 1000 combines high‐resolution imaging and high‐content analysis to provide a technology that rapidly detects and quantifies cellular properties that are not amenable for analysis by conventional methods.

Molecular Discovery Systems

High‐content analysis utilises high‐resolution fluorescence imaging and advanced image analysis to evaluate cellular properties. It has emerged as a powerful technology used by pharmaceutical and biotech industries in their drug discovery programmes, as it permits high‐throughput analysis of complex drug targets while minimising off‐target hits. Following are examples of high‐content live cell assays

Nuclear trafficking

+TGF

‐TGFHigh‐Content

Analysis

Custom made protocols

G1 G2 M

Cell Cycle

used at MDSystems:

High‐ThroughputScreening

UPS inhibition Induction of target expression

Proliferation

Mouse FBD fibre

0 hours 24 hours 48 hours Untreated

MG132 treated

19/03/2010

17

Tumour Suppressor Gene HLS5

BPH’s tumour suppressor gene project was reported by Professor Klinken's team in 2004. In conjunction with BPH Corporate the expert team at The West Australian Institute for Medical Research (WAIMR) led by Director Professor Peter Klinken are continuing with the research.

Currently the team is investigating the tumor suppressor gene HLS5 and its potential influence in Cancer. However, the concerted research efforts previously undertaken reveal that HLS5 works through multiple pathways that may target cancer as well as a range of other diseases.

BPH has developed an extensive patent portfolio and has exclusive rights to the tumor suppressor gene HLS5 both as a potential therapeutic target and also underpinning its involvement in a variety of disease pathways. The patent portfolio of technology surrounding HLS5 is currently going through National Phase filings in Australia, US

d E Th T S G HLS5 h l t f d t th d

Tumour Suppressor Gene HLS5

and Europe. The Tumor Suppressor Gene HLS5 has a large amount of data gathered with the continued support of the Western Australian Institute for Medical Research.

BPH is seeking out‐licensing or co‐development opportunities with large pharma / biotech.

Therapeutic TargetT S G

Anti‐Cancer TherapyG ThTumour Suppressor Gene

Regulates transcription / signaling pathwaysGene Therapy

Small molecules

Biomarker / Diagnostic AssaysDetect presence and severity of disease

Determine types of cancer and patients to target

Screening Assays / Research ToolsTo find compounds for anti‐cancer therapy

To determine MoA and relevance to disease

19/03/2010

18

Diagnostic Array Systems (DAS)

Technology

The BacTrak System is a diagnostic test for the detection of respiratory infections (e.g. diagnosis of pneumonia, Tuberculosis (TB) and Legionella disease). Our system identifies the cause of disease by testing for multiple bacteria in a single sputum sample quickly, efficiently and more accurately than current techniques.

Current Status

The research has been completed with in‐house validation and we have now initiated discussions with third parties to license the technology and progress the product to market.

Intellectual Property

Th IP (PCT WO 2007/012131 A1) l ll h d f id if i iThe IP (PCT WO 2007/012131 A1) relates generally to a method of identifying micro‐organisms in a sample using a tuf gene variable region. Currently going through national phase in Australia, China, Europe, Japan and the US.

Diagnostic Array Systems (DAS)

Conventional Method

• Not automated• Requires 2-3 days or several weeks for some

bacteria• Single test at a time• Uncertain results

BacTrak Method

• Most of the procedure automated• Requires only 4-5 hours for all bacteria

• Multiple tests done simultaneously• Accurate resultsUncertain results

• Success rate 20%• Requires bacterial targeting• Disposal of tests require additional safety

procedures as bacteria remain infective

Accurate results• Success rate 90-100%• Does not require bacterial targeting• Disposal of tests does not require additional

safety procedures as no live organisms used

BacTrak Data

• Assay validated for 16 pathogens• SOP’s in place• Software in development• Tuf gene exemplified as gene of choice

BacTrak Process

g p g• Success rate 90-100%

The objective is for a diagnostic company to license the BacTrak technology in the field of respiratory infection diagnosis.

19/03/2010

19

Technology

• Brain activity monitor that measures EEG• Algorithm based on physiology underlying the

EEG signal

Cortical Dynamics

Product

• Brain Anaesthesia Response (BAR) Monitor• Other potential uses: Neurodiagnostics and drug

monitoring. The market for depth of anaesthesia monitoring and Neurodiagnostics is expected to reach around US$1 billion by 2010.

Current Status

• Prototype monitor developed and built• Clinical trials of algorithm in progress

Intellectual Property

Cortical Dynamics patent portfolio is currently going through national phase in Australia, Europe, China, New Zealand and the US.

• The Cortical Dynamics BAR analysis is based on the physiological mechanisms that generate brain electrical activity allowing the BAR Monitor to be quicker, far more sensitive and accurate than existing monitors.

• The Cortical Dynamics team have completed two clinical trials both

Cortical Dynamics

conducted at The Royal Melbourne Hospital.

• The trials proved scientific acceptance for the Brain Anaesthesia Response (BAR) analysis methodology and shows superiority over existing monitoring approaches.

• The current program is to trial the BAR’s sensitivity with the most commonly used anaesthetic drugs.

• The team has published in the peer reviewed international journalComputers in Biology and Medicine.

• Cortical Dynamics has initiated discussions for the licensing of this technology with leading global companies in this sector.

19/03/2010

20

Summary

• The investment in Advent Energy represents an excellent investment opportunity for BPH.

•Significant potential return for investors from all investments and j tprojects.

• Current licence and commercial opportunities in three of its project portfolio.

• Anti-cancer therapeutic and the BAR monitor both address product areas which have $1 billion US market size.

• The DAS BacTrak product has global market application.

• Commercial outcomes have capacity to significantly impact on the company in the near term.

Risk Factors

A number of risk factors may adversely affect BPH Corporate Ltd (“BPH Corporate” or “BPH” or the “Company”) and its subsidiaries (collectively the “Group”). Below is a brief summary of some of the risk factors relevant for the Group. Any of the following risks could cause the trading price of securities issued by BPH to decline, and all or part of an investment being lost. Please note that the risks described below are not exhaustive, and other risks not discussed herein may also adversely affect the Group, its operations and future prospects.

The Group is dependent on its ability to find, appraise, acquire, develop and commercially produce oil and gas reserves.The Group is dependent on its ability to appraise, find, acquire, develop and commercially produce oil and gas reserves. The Group must continually locate and develop or acquire new reserves to replace reserves that are being depleted by production. Significant expenditure is required to establish the extent of oil and gas reserves through seismic and other surveys and drilling and there can be no certainty that oil and gas reserves will be found.Reserves and resources information represents estimates which may be inaccurate or incorrectThe reserves and resources data included in this Presentation are estimates. In general, estimates of the quantity and value of economically recoverable oil and gas reserves and resources and the possible future net cash flows are based upon a number of variable factors and assumptions, all of which may vary from actual results. The Group's estimates of its contingent and prospective resources are uncertain and can change with time and there can be no guarantee that the Group will be able to develop these resources commercially.Substantial investment will be necessary in the futureThe Group will be required to make substantial capital expenditure for the acquisition, exploration, development, production and abandonment of oil and gas reserves and facilities in the future. Such capital expenditures could be covered by revenues, new equity or by obtaining new debt. If the Group’s revenues decline, if the Company is unable to attract investors to increase the Company’s equity, or if new debt arrangements are not accessible, or only on unattractive commercial terms, the Group will experience a limited ability to undertake or complete future exploration programs, development investments, acquisitions.Oil and gas prices may not remain at their current levelsThe profitability and cash flow of the Group’s operations will be dependent upon the market price of oil and gas. It is impossible to predict accurately future oil and gas price movements. Accordingly, oil and gas prices may not remain at their current levels. The economics of developing or producing from some of the Group's prospects, reserves or wells may change as a result of lower prices, which could result in a reduction in the volumes of the Group's reserves if some are no longer economically viable to develop. This could result in a material decrease in the Group's net production revenue causing a reduction in its oil and gas acquisition, development and exploration activities and financial condition.Changes in the legislative and fiscal framework may affect profitabilityChanges in the legislative and fiscal framework governing the activities of the companies engaged within the oil and gas sector may have a material impact on exploration and development activity or directly affect the Group’s operations. In particular, changes in political regimes will constitute a material risk factor for the Group’s operations in foreign countries. Further, the Group is faced with increasingly complex tax laws. The amounts of taxes the Group pays could increase substantially as a result of changes in, or new interpretations of, these laws, which could have a material adverse effect on its liquidity and results of operations. In order to conduct its operations in compliance with applicable laws and regulations, the Group must obtain licenses and permits from various government authorities. The Group may incur substantial costs in order to maintain compliance with these existing laws and regulations and additional costs if these laws are revised or if new laws affecting the Group's operations are passed. Furthermore, there can be no assurance that the Group will be able to obtain all necessary licenses and permits that may be required to carry out exploration, development and production operations on its properties.The Group is subject to environmental and HSE risksAll phases of the oil business present environmental risks and hazards and are subject to environmental regulation pursuant to a variety of international conventions and state and municipal laws and regulationsAll phases of the oil business present environmental risks and hazards and are subject to environmental regulation pursuant to a variety of international conventions and state and municipal laws and regulations. Compliance with environmental legislation can require significant expenditures and a breach may result in the imposition of fines and penalties, some of which may be material. The failure to comply with current HSE laws and regulations has and may in the future result in regulatory action, the imposition of fines or the payment of compensation to third parties.The Group operates in a highly competitive marketThe oil and gas industry is highly competitive in all its phases. The Group competes with other market players, some of which have greater financial resources, staff and facilities than those of the Group. Due to the strong competitive environment, the Group may be unable to acquire attractive suitable assets and to retain or recruit key personnel. As a result, the Group's revenues may decline over time and adversely affect its results of operations or financial condition.Lack of Due Diligence InvestigationsNo independent due diligence investigations have been conducted prior to the offer set out in this presentation, and the Company may be subject to material losses or claims which the Company is not aware of at the date of this presentation.Financial RiskFinancial risk include the risk that the Company’s debt arrangements may restrict the Group’s business going forward, the risk of not being able to refinance existing debt, the risk of not being able to comply with covenants of a general, financial and technical nature, and risk associated with exchange rate fluctuation.Other Operational RiskWhile the Group operates most of its assets, it is not the operator of some of its current exploration assets. A third party operator’s mismanagement of an asset may result in delays or increased costs to the Group. While the Group has purposefully acquired interests in assets that are operated by operators it believes to be reputable, there can be no assurance that the operator will observe such standards or requirements. Further, the Group holds interests in exploration licenses in their initial terms. The early stages or exploration period of a license commonly involves the highest levels of risk. These phases of the license term require the high levels of relatively speculative capital expenditure without a commensurate degree of certainty of a return on that investment.

19/03/2010

21

Disclaimer

This Presentation has been prepared by BPH Corporate Ltd (the “Company”) and Advent Energy Ltd , solely for use at the presentation to investors held in connection with the proposed placement of shares by the Company and may not be reproduced or redistributed, in whole or in part, to any other person. To the best of the knowledge of the Company and its board of directors, the information contained in this Presentation is in all material respects in accordance with the facts as of the date hereof, and contains no material omissions likely to affect its import. However, neither the Company nor its directors, makes any representation or warranty (express or implied) as to, and no reliance should be placed on, any information, including projections, estimates, targets and opinions, contained herein, and no liability whatsoever is accepted as to any errors, omissions or misstatements contained herein, and, accordingly, none of the Company or any of their parent or subsidiary undertakings or any such person’s directors, officers or employees accepts any liability whatsoever arising directly or indirectly from the use of this Presentation. This Presentation also contains information obtained from third parties. Such information has been accurately reproduced and, as far as the Company is aware and able to ascertain from the information published by that third party, no facts have been omitted that would render the reproduced information to be inaccurate or misleading.This Presentation contains certain forward‐looking statements relating to the business, financial performance and results of the Company and/or the industry in which it operates. Forward‐looking statements concern future circumstances and results and other statements that are not historical facts, sometimes identified by the words “believes”, expects”, “predicts”, “intends”, “projects”, “plans”, “estimates”, “aims”, “foresees”, “anticipates”, “targets”, and similar expressions. The forward‐looking statements contained in this Presentation, including assumptions, opinions and views of the Company or cited from thi d t l l i i d f t hi h bj t t i k t i ti d th f t th t t l t t diff t i ll f ti i t d d l t N f ththird party sources are solely opinions and forecasts which are subject to risks, uncertainties and other factors that may cause actual events to differ materially from any anticipated development. None of the Company or any of their parent or subsidiary undertakings or any such person’s directors, officers or employees provide any assurance that the assumptions underlying such forward‐looking statements are free from errors, nor do any of them accept any responsibility for the future accuracy of the opinions expressed in this Presentation or the actual occurrence of the forecasted developments. The Company does not assume any obligation, except as required by law, to update any forward‐looking statements or to conform these forward‐looking statements to our actual results.AN INVESTMENT IN THE COMPANY INVOLVES RISK, AND SEVERAL FACTORS COULD CAUSE THE ACTUAL RESULTS, PERFORMANCE OR ACHIEVEMENTS OF THE COMPANY TO BE MATERIALLY DIFFERENT FROM ANY FUTURE RESULTS, PERFORMANCE OR ACHIEVEMENTS THAT MAY BE EXPRESSED OR IMPLIED BY STATEMENTS AND INFORMATION IN THIS PRESENTATION, INCLUDING, AMONG OTHERS, RISKS OR UNCERTAINTIES ASSOCIATED WITH THE COMPANY’S BUSINESS, SEGMENTS, DEVELOPMENT, GROWTH MANAGEMENT, FINANCING, MARKET ACCEPTANCE AND RELATIONS WITH CUSTOMERS, AND, MORE GENERALLY, GENERALECONOMIC AND BUSINESS CONDITIONS, CHANGES IN DOMESTIC AND FOREIGN LAWS AND REGULATIONS, TAXES, CHANGES IN COMPETITION AND PRICING ENVIRONMENTS, FLUCTUATIONS IN CURRENCY EXCHANGE RATES AND INTEREST RATES AND OTHER FACTORS. SHOULD ONE OR MORE OF THESE RISKS OR UNCERTAINTIES MATERIALISE, OR SHOULD UNDERLYING ASSUMPTIONS PROVE INCORRECT, ACTUAL RESULTS MAY VARY MATERIALLY FROM THOSE DESCRIBED IN THIS PRESENTATION.By attending or receiving this Presentation you acknowledge that you will be solely responsible for your own assessment of the market and the market position of the Company and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the Company’s business. All inquiries relating to this Presentation should be directed to the Company. No other persons has been authorized to give any information, or make any representation on behalf of, the Company in connection with the private placement and, if given or made, such other information or representation must not be relied upon as having been authorized by the Company.This Presentation is confidential and is being communicated in the United Kingdom to persons who have professional experience, knowledge and expertise in matters relating to investments and are "investment professionals" for the purposes of article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 and only in circumstances where, in accordance with section 86(1) of the Financial and Services Markets Act 2000 ("FSMA") the requirement to provide an approved prospectus in accordance with the requirement under section 85 FSMA does not apply. Consequently, the Investor understands that the private placement may be offered only to "qualified investors" for the purposes of sections 86(1) and 86(7) FSMA, or to limited numbers of UK investors, or only where minima are placed on the consideration or denomination of securities that can be made available (all such persons being referred to as "relevant persons"). This Presentation is only directed at qualified investors and investment professionals and other persons should not rely on or act upon this Presentation or any of its contents. Any investment or investment activity to which this communication relates is only available to and will only be engaged in with investment professionals. This Presentation (or any part of it) is not to be reproduced, distributed, passed on, or the contents otherwise divulged, directly or indirectly, to any other person (excluding an investment professional’s advisers) without the prior written consent of the Company.IN RELATION TO THE UNITED STATES AND U.S. PERSONS, THIS PRESENTATION IS STRICTLY CONFIDENTIAL AND IS BEING FURNISHED SOLELY IN RELIANCE ON APPLICABLE EXEMPTIONS FROM THE REGISTRATION REQUIREMENTS UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED. THE SHARES HAVE NOT AND WILL NOT BE REGISTERED UNDER THE U.S. SECURITIES ACT OR ANY STATE SECURITIES LAWS, AND MAY NOT BE OFFERED OR SOLD WITHIN THE UNITED STATES, OR TO OR FOR THE ACCOUNT OR BENEFIT OF U.S. PERSONS, UNLESS AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE U.S. SECURITIES ACT ISAVAILABLE. ACCORDINGLY, ANY OFFER OR SALE OF SHARES WILL ONLY BE OFFERED OR SOLD (I) WITHIN THE UNITED STATES, OR TO OR FOR THE ACCOUNT OR BENEFIT OF U.S. PERSONS, ONLY TO QUALIFIED INSTITUTIONAL BUYERS (“QIBs”) IN PRIVATE PLACEMENT TRANSACTIONS NOT INVOLVING A PUBLIC OFFERING AND (II) OUTSIDE THE UNITED STATES IN OFFSHORE TRANSACTIONS IN ACCORDANCE WITH REGULATION S. ANY PURCHASER OF SHARES IN THE UNITED STATES, OR TO OR FOR THE ACCOUNT OF U.S. PERSONS, WILL BE DEEMED TO HAVE MADE CERTAIN REPRESENTATIONS AND ACKNOWLEDGEMENTS, INCLUDING WITHOUTLIMITATION THAT THE PURCHASER IS A QIB.The distribution of this Presentation may in certain jurisdictions be restricted by law. Persons in possession of this Presentation are required to inform themselves about and to observe any such restrictions. This Presentation does not constitute an offer of, or an invitation to subscribe or purchase, any of the Company’s shares or bonds. This Presentation speaks as of XX XXXX 2009. Neither the delivery of this Presentation nor any further discussions of the Company with any of the recipients shall, under any circumstances, create any implication that there has been no change in the affairs of the Company since such date.

14 View StreetNorth Perth Western Australia 6006

Australia

Telephone: +61 8 9328 8366

ABN 41 095 912 002

pFacsimile: +61 8 9328 8733

Email: admin@bphcorporate.com.auWebsite: www.bphcorporate.com.au